Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tremelimumab + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination immunotherapy consisting of the anti-CTLA-4 monoclonal antibody tremelimumab and recombinant interferon alfa-2b investigated primarily for advanced melanoma. Tremelimumab blocks CTLA-4 to enhance T-cell activation and antitumor immunity, while interferon alfa-2b exerts immunomodulatory and antineoplastic effects; together they were studied for potential additive or synergistic activity. A phase II study administered tremelimumab 15 mg/kg IV every 12 weeks with concurrent high-dose interferon alfa-2b induction (20 MU/m2/day IV, 5 days/week for 4 weeks) followed by maintenance (10 MU/m2/day SC three times weekly for 8 weeks), showing acceptable toxicity and signs of durable antitumor efficacy in metastatic melanoma patients.[4] Tremelimumab is an IgG2 monoclonal antibody targeting CTLA-4, developed by AstraZeneca/MedImmune; interferon alfa-2b is a recombinant type I interferon historically marketed as Intron A.[2][4][6]
- Brand names
- ImjudoIntron A
- Other names
- tremelimumab plus interferon alfa-2b
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on tremelimumab + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tremelimumab + interferon alfa-2b.